HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, X. Articles by Chen, X. Search for Related Content PubMed PubMed Citation Articles by Zhang, X. Articles by Chen, X.

Quantitative PET Imaging of Tumor Integrin _vß₃ Expression with ¹⁸F-FRGD2

Molecular Imaging Program at Stanford (MIPS), and Bio-X Program, Department of Radiology, Stanford University, Stanford, California

Correspondence: For correspondence or reprints contact: Xiaoyuan Chen, PhD, Department of Radiology, 1201 Welch Rd., P095, Stanford University, Stanford, CA 94305-5484. E-mail: shawchen{at}stanford.edu

The development of noninvasive methods to visualize and quantify integrin _vß₃ expression in vivo appears to be crucial for the success of antiangiogenic therapy based on integrin antagonism. Precise documentation of integrin receptor levels will allow appropriate selection of patients who will most likely benefit from an antiintegrin treatment regimen. Imaging can also be used to provide an optimal dosage and time course for treatment based on receptor occupancy studies. In addition, imaging integrin expression will be important to evaluate antiintegrin treatment efficacy and to develop new therapeutic drugs with favorable tumor targeting and in vivo kinetics. We labeled the dimeric RGD peptide E[c(RGDyK)]₂ with ¹⁸F and evaluated its tumor-targeting efficacy and pharmacokinetics of ¹⁸F-FB–E[c(RGDyK)]₂ (¹⁸F-FRGD2). Methods: E[c(RGDyK)]₂ was labeled with ¹⁸F by conjugation coupling with N-succinimidyl-4-¹⁸F-fluorobenzoate (¹⁸F-SFB) under a slightly basic condition. The in vivo metabolic stability of ¹⁸F-FRGD2 was determined. The diagnostic value after injection of ¹⁸F-FRGD2 was evaluated in various xenograft models by dynamic microPET followed by ex vivo quantification of tumor integrin level. Results: Starting with ¹⁸F^– Kryptofix 2.2.2./K₂CO₃ solution, the total reaction time for ¹⁸F-FRGD2, including final high-performance liquid chromatography purification, is about 200 ± 20 min. Typical decay-corrected radiochemical yield is 23% ± 2% (n = 20). ¹⁸F-FRGD2 is metabolically stable. The binding potential extrapolated from graphical analysis of PET data and Logan plot correlates well with the receptor density measured by sodium dodecyl sulfate polyacrylamide electrophoresis and autoradiography in various xenograft models. The tumor-to-background ratio at 1 h after injection of ¹⁸F-FRGD2 also gives a good linear relationship with the tumor tissue integrin level. Conclusion: The dimeric RGD peptide tracer ¹⁸F-FRGD2, with high integrin specificity and favorable excretion profile, may be translated into the clinic for imaging integrin _vß₃ expression. The binding potential calculated from simplified tracer kinetic modeling such as the Logan plot appears to be an excellent indicator of tumor integrin density.

Key Words: molecular imaging • integrin _vß₃ • dimeric RGD peptide • dynamic microPET • Logan plot

This article has been cited by other articles:

				G. Ren, Z. Liu, Z. Miao, H. Liu, M. Subbarayan, F. T. Chin, L. Zhang, S. S. Gambhir, and Z. Cheng PET of Malignant Melanoma Using 18F-Labeled Metallopeptides J. Nucl. Med., November 1, 2009; 50(11): 1865 - 1872. [Abstract] [Full Text] [PDF]

				R. A. Dumont, I. Hildebrandt, H. Su, R. Haubner, G. Reischl, J. G. Czernin, P. S. Mischel, and W. A. Weber Noninvasive Imaging of {alpha}V{beta}3 Function as a Predictor of the Antimigratory and Antiproliferative Effects of Dasatinib Cancer Res., April 1, 2009; 69(7): 3173 - 3179. [Abstract] [Full Text] [PDF]

				R. H. Kimura, Z. Cheng, S. S. Gambhir, and J. R. Cochran Engineered Knottin Peptides: A New Class of Agents for Imaging Integrin Expression in Living Subjects Cancer Res., March 15, 2009; 69(6): 2435 - 2442. [Abstract] [Full Text] [PDF]

				I. Burvenich, S. Schoonooghe, L. Vervoort, C. Dumolyn, E. Coene, L. Vanwalleghem, J. Van Huysse, M. Praet, C. Cuvelier, N. Mertens, et al. Monoclonal antibody 14C5 targets integrin {alpha}v{beta}5 Mol. Cancer Ther., December 1, 2008; 7(12): 3771 - 3779. [Abstract] [Full Text] [PDF]

				P. M. Winter, A. H. Schmieder, S. D. Caruthers, J. L. Keene, H. Zhang, S. A. Wickline, and G. M. Lanza Minute dosages of {alpha}{nu}{beta}3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits FASEB J, August 1, 2008; 22(8): 2758 - 2767. [Abstract] [Full Text] [PDF]

				W. Cai and X. Chen Multimodality Molecular Imaging of Tumor Angiogenesis J. Nucl. Med., June 1, 2008; 49(Suppl_2): 113S - 128S. [Abstract] [Full Text] [PDF]

				J. M. Jeong, M. K. Hong, Y. S. Chang, Y.-S. Lee, Y. J. Kim, G. J. Cheon, D. S. Lee, J.-K. Chung, and M. C. Lee Preparation of a Promising Angiogenesis PET Imaging Agent: 68Ga-Labeled c(RGDyK)-Isothiocyanatobenzyl-1,4,7-Triazacyclononane-1,4,7-Triacetic Acid and Feasibility Studies in Mice J. Nucl. Med., May 1, 2008; 49(5): 830 - 836. [Abstract] [Full Text] [PDF]

				H. Wang, K. Chen, W. Cai, Z. Li, L. He, A. Kashefi, and X. Chen Integrin-targeted imaging and therapy with RGD4C-TNF fusion protein Mol. Cancer Ther., May 1, 2008; 7(5): 1044 - 1053. [Abstract] [Full Text] [PDF]

				T. Higuchi, F. M. Bengel, S. Seidl, P. Watzlowik, H. Kessler, R. Hegenloh, S. Reder, S. G. Nekolla, H. J. Wester, and M. Schwaiger Assessment of {alpha}v{beta}3 integrin expression after myocardial infarction by positron emission tomography Cardiovasc Res, May 1, 2008; 78(2): 395 - 403. [Abstract] [Full Text] [PDF]

				M. Rodriguez-Porcel, W. Cai, O. Gheysens, J. K. Willmann, K. Chen, H. Wang, I. Y. Chen, L. He, J. C. Wu, Z.-b. Li, et al. Imaging of VEGF Receptor in a Rat Myocardial Infarction Model Using PET J. Nucl. Med., April 1, 2008; 49(4): 667 - 673. [Abstract] [Full Text] [PDF]

				Z.-B. Li, Z. Wu, K. Chen, E. K. Ryu, and X. Chen 18F-Labeled BBN-RGD Heterodimer for Prostate Cancer Imaging J. Nucl. Med., March 1, 2008; 49(3): 453 - 461. [Abstract] [Full Text] [PDF]

				D. S. Boss, R. V. Olmos, M. Sinaasappel, J. H. Beijnen, and J. H. M. Schellens Application of PET/CT in the Development of Novel Anticancer Drugs Oncologist, January 1, 2008; 13(1): 25 - 38. [Abstract] [Full Text] [PDF]

				Z. Wu, Z.-B. Li, K. Chen, W. Cai, L. He, F. T. Chin, F. Li, and X. Chen microPET of Tumor Integrin {alpha}v{beta}3 Expression Using 18F-Labeled PEGylated Tetrameric RGD Peptide (18F-FPRGD4) J. Nucl. Med., September 1, 2007; 48(9): 1536 - 1544. [Abstract] [Full Text] [PDF]

				S. H. Hausner, D. DiCara, J. Marik, J. F. Marshall, and J. L. Sutcliffe Use of a Peptide Derived from Foot-and-Mouth Disease Virus for the Noninvasive Imaging of Human Cancer: Generation and Evaluation of 4-[18F]Fluorobenzoyl A20FMDV2 for In vivo Imaging of Integrin {alpha}v{beta}6 Expression with Positron Emission Tomography Cancer Res., August 15, 2007; 67(16): 7833 - 7840. [Abstract] [Full Text] [PDF]

				R. Rossin, D. Berndorff, M. Friebe, L. M. Dinkelborg, and M. J. Welch Small-Animal PET of Tumor Angiogenesis Using a 76Br-Labeled Human Recombinant Antibody Fragment to the ED-B Domain of Fibronectin J. Nucl. Med., July 1, 2007; 48(7): 1172 - 1179. [Abstract] [Full Text] [PDF]

				Z.-b. Li, W. Cai, Q. Cao, K. Chen, Z. Wu, L. He, and X. Chen 64Cu-Labeled Tetrameric and Octameric RGD Peptides for Small-Animal PET of Tumor {alpha}v{beta}3 Integrin Expression J. Nucl. Med., July 1, 2007; 48(7): 1162 - 1171. [Abstract] [Full Text] [PDF]

				Z. Cheng, L. Zhang, E. Graves, Z. Xiong, M. Dandekar, X. Chen, and S. S. Gambhir Small-Animal PET of Melanocortin 1 Receptor Expression Using a 18F-Labeled {alpha}-Melanocyte-Stimulating Hormone Analog J. Nucl. Med., June 1, 2007; 48(6): 987 - 994. [Abstract] [Full Text] [PDF]

				W. Cai, T. Olafsen, X. Zhang, Q. Cao, S. S. Gambhir, L. E. Williams, A. M. Wu, and X. Chen PET Imaging of Colorectal Cancer in Xenograft-Bearing Mice by Use of an 18F-Labeled T84.66 Anti-Carcinoembryonic Antigen Diabody J. Nucl. Med., February 1, 2007; 48(2): 304 - 310. [Abstract] [Full Text] [PDF]

				K.-H. Jung, K.-H. Lee, J.-Y. Paik, B.-H. Ko, J.-S. Bae, B. C. Lee, H. J. Sung, D. H. Kim, Y. S. Choe, and D. Y. Chi Favorable Biokinetic and Tumor-Targeting Properties of 99mTc-Labeled Glucosamino RGD and Effect of Paclitaxel Therapy J. Nucl. Med., December 1, 2006; 47(12): 2000 - 2007. [Abstract] [Full Text] [PDF]

				W. Cai, K. Chen, K. A. Mohamedali, Q. Cao, S. S. Gambhir, M. G. Rosenblum, and X. Chen PET of Vascular Endothelial Growth Factor Receptor Expression J. Nucl. Med., December 1, 2006; 47(12): 2048 - 2056. [Abstract] [Full Text] [PDF]

				W. Cai, J. Rao, S. S. Gambhir, and X. Chen How molecular imaging is speeding up antiangiogenic drug development. Mol. Cancer Ther., November 1, 2006; 5(11): 2624 - 2633. [Abstract] [Full Text] [PDF]

				W. Cai, Y. Wu, K. Chen, Q. Cao, D. A. Tice, and X. Chen In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin {alpha}v{beta}3 Cancer Res., October 1, 2006; 66(19): 9673 - 9681. [Abstract] [Full Text] [PDF]

				W. A. Weber Positron Emission Tomography As an Imaging Biomarker J. Clin. Oncol., July 10, 2006; 24(20): 3282 - 3292. [Abstract] [Full Text] [PDF]

				W. Cai, X. Zhang, Y. Wu, and X. Chen A Thiol-Reactive 18F-Labeling Agent, N-[2-(4-18F-Fluorobenzamido)Ethyl]Maleimide, and Synthesis of RGD Peptide-Based Tracer for PET Imaging of {alpha}v{beta}3 Integrin Expression J. Nucl. Med., July 1, 2006; 47(7): 1172 - 1180. [Abstract] [Full Text] [PDF]